AstraZeneca, Ionis See Shares Drop Up to 12% After Wainua Fails Pivotal Heart Trial
Updated
Updated · STAT · Jul 9
AstraZeneca, Ionis See Shares Drop Up to 12% After Wainua Fails Pivotal Heart Trial
3 articles · Updated · STAT · Jul 9
Summary
Wainua failed to beat placebo in a pivotal ATTR-CM trial, missing its goal of reducing cardiovascular death and clinical events in patients with transthyretin-mediated amyloid cardiomyopathy.
AstraZeneca shares fell about 8% in U.S. premarket trading and 9% in London, while partner Ionis dropped 12% in premarket after the setback.
The miss is a blow to AstraZeneca's push in cardiovascular disease and undercuts its position in an increasingly competitive ATTR-CM market.
Wainua had been one of AstraZeneca's partnered bets in a field drawing heavy biopharma interest, so the failure shifts attention toward rival developers.